Heidelberg Pharma Toekomstige groei

Future criteriumcontroles 1/6

De winst van Heidelberg Pharma zal naar verwachting dalen met 33% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 19.1% per jaar. De winst per aandeel zal naar verwachting afnemen met 34.6% per jaar.

Belangrijke informatie

-33.0%

Groei van de winst

-34.6%

Groei van de winst per aandeel

Biotechs winstgroei	36.4%
Inkomstengroei	19.1%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	10 Oct 2024

Recente toekomstige groei-updates

Recent updates

Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?

Feb 16

Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues

Dec 05

Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%

Jul 21

Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%

Jan 17

We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

Dec 14

Winst- en omzetgroeiprognoses

XTRA:HPHA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
11/30/2026	13	-39	N/A	N/A	1
11/30/2025	12	-46	N/A	N/A	2
11/30/2024	10	-22	N/A	N/A	1
8/31/2024	8	-19	-30	-30	N/A
5/31/2024	10	-13	-33	-32	N/A
2/29/2024	9	-18	-34	-34	N/A
11/30/2023	10	-20	-35	-34	N/A
8/31/2023	9	-22	-35	-34	N/A
5/31/2023	11	-27	-35	-34	N/A
2/28/2023	20	-19	-14	-13	N/A
11/30/2022	19	-20	-9	-9	N/A
8/31/2022	17	-21	-9	-8	N/A
5/31/2022	13	-22	-7	-6	N/A
2/28/2022	2	-27	-28	-27	N/A
11/30/2021	2	-26	-28	-27	N/A
8/31/2021	2	-25	-25	-23	N/A
5/31/2021	7	-22	-24	-23	N/A
2/28/2021	7	-20	-21	-20	N/A
11/30/2020	9	-18	-19	-18	N/A
8/31/2020	10	-17	-18	-17	N/A
5/31/2020	7	-15	-12	-11	N/A
2/29/2020	8	-12	-11	-10	N/A
11/30/2019	7	-10	-10	-9	N/A
8/31/2019	7	-10	-10	-9	N/A
5/31/2019	6	-11	-12	-12	N/A
2/28/2019	4	-12	-11	-10	N/A
11/30/2018	4	-12	-11	-10	N/A
8/31/2018	4	-11	-11	-10	N/A
5/31/2018	3	-11	N/A	-8	N/A
2/28/2018	2	-11	N/A	-9	N/A
11/30/2017	2	-11	N/A	-8	N/A
8/31/2017	2	-10	N/A	-7	N/A
5/31/2017	2	-8	N/A	-8	N/A
2/28/2017	2	-7	N/A	-7	N/A
11/30/2016	2	-6	N/A	-7	N/A
8/31/2016	2	-7	N/A	-6	N/A
5/31/2016	2	-7	N/A	-5	N/A
2/29/2016	2	-7	N/A	-5	N/A
11/30/2015	3	-7	N/A	-5	N/A
8/31/2015	3	-5	N/A	-4	N/A
5/31/2015	5	-3	N/A	-3	N/A
2/28/2015	4	-4	N/A	-4	N/A
11/30/2014	4	-6	N/A	-7	N/A
8/31/2014	7	-5	N/A	-7	N/A
5/31/2014	9	-6	N/A	-10	N/A
2/28/2014	11	-6	N/A	-12	N/A
11/30/2013	14	-5	N/A	-14	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat HPHA de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat HPHA de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat HPHA de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van HPHA ( 19.1% per jaar) zal naar verwachting sneller groeien dan de markt German ( 5.5% per jaar).

Hoge groei-inkomsten: De omzet van HPHA ( 19.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van HPHA naar verwachting over 3 jaar hoog zal zijn

Heidelberg Pharma Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates upgraded to €0.39 loss

Price target increased by 33% to €8.90

Price target decreased by 24% to €6.70

Consensus revenue estimates increase by 21%

Price target decreased by 19% to €8.87

Consensus revenue estimates fall by 60%

Recent updates

Second quarter 2024 earnings released: €0.086 loss per share (vs €0.20 loss in 2Q 2023)

Consensus EPS estimates upgraded to €0.39 loss

Second quarter 2024 earnings released: €0.086 loss per share (vs €0.20 loss in 2Q 2023)

New major risk - Financial position

First quarter 2024 earnings released: €0.10 loss per share (vs €0.14 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 33% to €8.90

Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?

Heidelberg Pharma AG to Report First Half, 2024 Results on Jul 11, 2024

Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues

Price target decreased by 24% to €6.70

Third quarter 2023 earnings released: EPS: €0.002 (vs €0.14 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101

Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%

Consensus revenue estimates increase by 21%

Second quarter 2023 earnings released

Heidelberg Pharma Ag Announces Executive Changes

Price target decreased by 19% to €8.87

Consensus revenue estimates fall by 60%

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 8.0% to €10.30

Consensus forecasts updated

Consensus revenue estimates increase by 83%

Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher

Third quarter 2022 earnings released: €0.14 loss per share (vs €0.17 loss in 3Q 2021)

Second quarter 2022 earnings released: €0.04 loss per share (vs €0.22 loss in 2Q 2021)

Heidelberg Pharma AG Provides Earnings Guidance for the Year 2022

Consensus revenue estimates increase by 87%

First quarter 2022 earnings: EPS misses analyst expectations

Price target increased to €10.78

Heidelberg Pharma AG announced that it expects to receive €36 million in funding

Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma

Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely

Third quarter 2021 earnings released: €0.17 loss per share (vs €0.096 loss in 3Q 2020)

Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 in the US

CEO, CFO & Member of the Executive Management Board Jan Schmidt-Brand has left the company

Heidelberg Pharma AG Provides Financial Guidance for 2021

Forecast to breakeven in 2023

Second quarter 2021 earnings released: €0.22 loss per share (vs €0.17 loss in 2Q 2020)

Heidelberg Pharma to Present Its Proprietary ATAC Technology

Consensus revenue estimates fall to €7.56m

First quarter 2021 earnings released: €0.20 loss per share (vs €0.16 loss in 1Q 2020)

Heidelberg Pharma AG Reaffirms Earnings Guidance for 2021

Full year 2020 earnings released: €0.61 loss per share (vs €0.36 loss in FY 2019)

Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be

Heidelberg Pharma AG Provides Earnings Guidance for the Year 2021

We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

Heidelberg Pharma AG Heidelberg Pharma Expands Management Team

New 90-day high: €7.68

Heidelberg Pharma AG and Indiana University Publish Results on HER2-ATAC for Targeted Immunotherapy of Triple Negative Breast Cancer in Science Translational Medicine

Price target raised to €6.52

Heidelberg Pharma AG Announces FDA Allows the Company to Start A Phase I/IIa Clinical Trial with ATAC Candidate HDP-101

Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%

Heidelberg Pharma AG, Annual General Meeting, May 18, 2021

We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

New 90-day high: €5.94

New 90-day high: €4.90

Heidelberg Pharma AG Announces Several Presentations of Research Results on ATAC Technology At the ASH Annual Meeting 2020

Analysts update estimates

New 90-day low: €3.69

Heidelberg Pharma AG Updates Financial Guidance for the Year 2020

Third quarter earnings released

New 90-day low: €3.91

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen